Adaptimmune Therapeutics (NASDAQ:ADAP) Announces Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Adaptimmune Therapeutics (NASDAQ:ADAP) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09), Zacks reports. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%.

Adaptimmune Therapeutics Price Performance

NASDAQ:ADAP traded down $0.01 during mid-day trading on Monday, hitting $0.28. 2,891,945 shares of the stock traded hands, compared to its average volume of 1,687,464. The business’s 50-day moving average price is $0.54 and its 200 day moving average price is $0.69. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The company has a market cap of $70.83 million, a PE ratio of -1.26 and a beta of 2.52. Adaptimmune Therapeutics has a 12-month low of $0.26 and a 12-month high of $1.65.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Scotiabank cut their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research note on Friday. Mizuho reduced their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Wells Fargo & Company lowered their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research report on Friday. Finally, StockNews.com initiated coverage on shares of Adaptimmune Therapeutics in a report on Friday. They issued a “buy” rating for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $2.18.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.